Reddy 博士的索马鲁肽在加拿大的批准被推迟，损害了股价并面临 $100M 收入的风险。 Dr Reddy’s semaglutide approval delayed in Canada, hurting shares and risking $100M in revenue.

Reddy博士的实验室股份在BSE上下跌了4-6%,在NYSE上下跌了8%以上。 在加拿大卫生管理者发布一份不遵约通知,要求其进行硫酸盐注射,要求提供补充资料并推迟批准之后,Reddy博士的实验室股份在BSE上下跌了4-6%,而在NYSE上跌了8%以上。 Dr Reddy’s Laboratories shares dropped 4-6% on the BSE and over 8% on the NYSE after Canada’s health regulators issued a Notice of Non-Compliance for its semaglutide injection submission, requesting additional information and delaying approval. 这一挫折与该公司努力推出Novo Nordisk的Wegovy和Ozempic的通用版本有关,可能会将加拿大的发射推到2026年底,可能使预期收入损失高达1亿美元。 The setback, linked to the company’s efforts to launch a generic version of Novo Nordisk’s Wegovy and Ozempic, may push the launch in Canada to late 2026, potentially costing up to $100 million in expected revenue. 该公司肯定了对其产品质量的信心,并承诺及时作出回应。 The company affirmed confidence in its product’s quality and pledged a timely response.